Edelstein et al., 2023 - Google Patents
SARS-CoV-2 virologic rebound with nirmatrelvir–ritonavir therapy: an observational studyEdelstein et al., 2023
View PDF- Document ID
- 14017775428246423629
- Author
- Edelstein G
- Boucau J
- Uddin R
- Marino C
- Liew M
- Barry M
- Choudhary M
- Gilbert R
- Reynolds Z
- Li Y
- Tien D
- Sagar S
- Vyas T
- Kawano Y
- Sparks J
- Hammond S
- Wallace Z
- Vyas J
- Barczak A
- Lemieux J
- Li J
- Siedner M
- Publication year
- Publication venue
- Annals of Internal Medicine
External Links
Snippet
Background: Data are conflicting regarding an association between treatment of acute COVID-19 with nirmatrelvir− ritonavir (NR) and virologic rebound (VR). Objective: To compare the frequency of VR in patients with and without NR treatment for acute COVID-19 …
Classifications
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/32—Medical data management, e.g. systems or protocols for archival or communication of medical images, computerised patient records or computerised general medical references
- G06F19/322—Management of patient personal data, e.g. patient records, conversion of records or privacy aspects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/36—Computer-assisted acquisition of medical data, e.g. computerised clinical trials or questionnaires
- G06F19/366—Acquisition of data related to laboratory tests, e.g. special identifiers for examination containers
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/34—Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
- G06F19/345—Medical expert systems, neural networks or other automated diagnosis
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
- G06Q50/24—Patient record management
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F17/00—Digital computing or data processing equipment or methods, specially adapted for specific functions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q10/00—Administration; Management
- G06Q10/10—Office automation, e.g. computer aided management of electronic mail or groupware; Time management, e.g. calendars, reminders, meetings or time accounting
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Edelstein et al. | SARS-CoV-2 virologic rebound with nirmatrelvir–ritonavir therapy: an observational study | |
Oliver et al. | Group A Streptococcus pharyngitis and pharyngeal carriage: a meta-analysis | |
Follmann et al. | Antinucleocapsid antibodies after SARS-CoV-2 infection in the blinded phase of the randomized, placebo-controlled mRNA-1273 COVID-19 vaccine efficacy clinical trial | |
Mariani et al. | CureGN study rationale, design, and methods: establishing a large prospective observational study of glomerular disease | |
McKay et al. | Performance evaluation of serial SARS-CoV-2 rapid antigen testing during a nursing home outbreak | |
Schrom et al. | Comparison of SARS-CoV-2 reverse transcriptase polymerase chain reaction and BinaxNOW rapid antigen tests at a community site during an Omicron surge: a cross-sectional study | |
Tabone et al. | Blood transcriptomics reveal the evolution and resolution of the immune response in tuberculosis | |
Gupta et al. | Prevalent and incident tuberculosis are independent risk factors for mortality among patients accessing antiretroviral therapy in South Africa | |
Tang et al. | Assessment of SARS-CoV-2 seropositivity during the first and second viral waves in 2020 and 2021 among Canadian adults | |
Nijman et al. | C-reactive protein bedside testing in febrile children lowers length of stay at the emergency department | |
Briggs et al. | Seroprevalence of antibodies to SARS-CoV-2 in rural households in Eastern Uganda, 2020-2022 | |
Ochodo et al. | Point‐of‐care viral load tests to detect high HIV viral load in people living with HIV/AIDS attending health facilities | |
Rogozińska et al. | On‐site test to detect syphilis in pregnancy: a systematic review of test accuracy studies | |
Ochodo et al. | Point‐of‐care tests detecting HIV nucleic acids for diagnosis of HIV‐1 or HIV‐2 infection in infants and children aged 18 months or less | |
Samsunder et al. | Clinical evaluation of severe acute respiratory syndrome coronavirus 2 rapid antigen tests during the omicron wave in South Africa | |
Fu et al. | Rapid immunodot AQP4 assay for neuromyelitis optica spectrum disorder | |
Schramm et al. | Potential value of urine lateral-flow lipoarabinomannan (LAM) test for diagnosing tuberculosis among severely acute malnourished children | |
Olbrich et al. | Rapid and accurate diagnosis of pediatric tuberculosis disease: a diagnostic accuracy study for pediatric tuberculosis | |
Taher et al. | Implementation of serological and molecular tools to inform COVID-19 patient management: protocol for the GENCOV prospective cohort study | |
Gils et al. | Implementation of the advanced HIV disease care package with point-of-care CD4 testing during tuberculosis case finding: A mixed-methods evaluation | |
Cochrane Infectious Diseases Group et al. | Impact of diagnostic strategies for tuberculosis using lateral flow urine lipoarabinomannan assay in people living with HIV | |
Adriaenssens et al. | Prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study with 12 months of follow-up | |
Yan et al. | Predictors of coronavirus disease 2019 hospitalization after sotrovimab in patients with hematologic malignancy during the BA. 1 Omicron surge | |
Wertenauer et al. | Diagnostic efficacy of rapid antigen testing for SARS-CoV-2: the COVid-19 AntiGen (COVAG) study | |
Agarwal et al. | Performance and variability of QuantiFERON Gold Plus assay associated with phlebotomy type |